Literature DB >> 23307251

Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer.

Wenzhuo He1, Chenxi Yin, Guifang Guo, Chang Jiang, Fang Wang, Huijuan Qiu, Xuxian Chen, Ruming Rong, Bei Zhang, Liangping Xia.   

Abstract

The prognostic, especially predictive, values of inflammation indexes in advanced colorectal cancer were not established. Therefore, the both values of neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) in patients with initially metastatic colorectal cancer (mCRC) were investigated and compared. Samples were collected from 243 patients who were initially diagnosed with mCRC between 2005 and 2010 in the Sun Yat-sen University Cancer Center. Elevated NLR (p < 0.001), PLR (p = 0.008), and CEA (p < 0.001) were identified as statistically significant poor prognostic factors for overall survival (OS), while only NLR (p = 0.029) and CEA (p < 0.001) were validated as independent predictors. Univariate analysis identified elevated NLR (p < 0.001), PLR (p = 0.023), and CEA (p < 0.001) as statistically significant poor predict factors for the progression-free survival (PFS) of first-line chemotherapy, while NLR (p = 0.013) and CEA (p = 0.001) were independent. In addition, we observed significantly different OS (p < 0.001) and PFS (p < 0.001) among patients who had elevations in both NLR and CEA levels and those having one elevation or neither elevation. NLR, PLR, and CEA were significant predictors of OS and PFS in mCRC. However, only NLR and CEA play as independent. When coupled with CEA, NLR may lead to improved prognostic predictors.

Entities:  

Mesh:

Year:  2013        PMID: 23307251     DOI: 10.1007/s12032-012-0439-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer.

Authors:  S R Walsh; E J Cook; F Goulder; T A Justin; N J Keeling
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

3.  Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer.

Authors:  H J Wanebo; B Rao; C M Pinsky; R G Hoffman; M Stearns; M K Schwartz; H F Oettgen
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

4.  DNA methylation predicts recurrence from resected stage III proximal colon cancer.

Authors:  Joong Bae Ahn; Woon Bok Chung; Osamu Maeda; Sang Joon Shin; Hyun Soo Kim; Hyun Chul Chung; Nam Kyu Kim; Jean-Pierre J Issa
Journal:  Cancer       Date:  2010-11-18       Impact factor: 6.860

5.  Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.

Authors:  Aziz Zaanan; Jean-François Fléjou; Jean-François Emile; Guetz Gaëtan Des; Peggy Cuilliere-Dartigues; David Malka; Cédric Lecaille; Pierre Validire; Christophe Louvet; Philippe Rougier; Aimery de Gramont; Franck Bonnetain; Françoise Praz; Julien Taïeb
Journal:  Clin Cancer Res       Date:  2011-10-13       Impact factor: 12.531

Review 6.  Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer.

Authors:  Mitchell J Goldstein; Edith Peterson Mitchell
Journal:  Cancer Invest       Date:  2005       Impact factor: 2.176

Review 7.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

8.  An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study.

Authors:  M J Proctor; D S Morrison; D Talwar; S M Balmer; D S J O'Reilly; A K Foulis; P G Horgan; D C McMillan
Journal:  Br J Cancer       Date:  2011-01-25       Impact factor: 7.640

9.  Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer.

Authors:  W Chua; K A Charles; V E Baracos; S J Clarke
Journal:  Br J Cancer       Date:  2011-03-29       Impact factor: 7.640

10.  Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer.

Authors:  E F Leitch; M Chakrabarti; J E M Crozier; R F McKee; J H Anderson; P G Horgan; D C McMillan
Journal:  Br J Cancer       Date:  2007-10-09       Impact factor: 7.640

View more
  83 in total

1.  Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.

Authors:  Anna Song; Wankyu Eo; Sookyung Lee
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

2.  Venous Thromboembolism Is an Independent Predictor of Mortality Among Patients with Gastric Cancer.

Authors:  Harry E Fuentes; D M Oramas; L H Paz; Y Wang; X A Andrade; A J Tafur
Journal:  J Gastrointest Cancer       Date:  2018-12

3.  Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer.

Authors:  Hongbing Liu; Ying Wu; Zhaofeng Wang; Yanwen Yao; Fangfang Chen; He Zhang; Yunfen Wang; Yong Song
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

4.  Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study.

Authors:  Susumu Inamoto; Kenji Kawada; Ryosuke Okamura; Koya Hida; Yoshiharu Sakai
Journal:  Int J Colorectal Dis       Date:  2019-06-08       Impact factor: 2.571

5.  Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy.

Authors:  Gui-Ming Zhang; Yao Zhu; Lei Luo; Fang-Ning Wan; Yi-Ping Zhu; Li-Jiang Sun; Ding-Wei Ye
Journal:  Tumour Biol       Date:  2015-06-02

6.  Pretreatment platelet-to-lymphocyte ratio is associated with the response to first-line chemotherapy and survival in patients with metastatic gastric cancer.

Authors:  Jin Wang; Jinglei Qu; Zhi Li; Xiaofang Che; Jing Liu; Yuee Teng; Bo Jin; Mingfang Zhao; Yunpeng Liu; Xiujuan Qu
Journal:  J Clin Lab Anal       Date:  2017-02-26       Impact factor: 2.352

7.  Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients.

Authors:  Wei-wei Zhang; Ke-jun Liu; Guo-lin Hu; Wei-jiang Liang
Journal:  Tumour Biol       Date:  2015-06-11

8.  Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor.

Authors:  Kyriakos Neofytou; Elizabeth C Smyth; Alexandros Giakoustidis; Aamir Z Khan; David Cunningham; Satvinder Mudan
Journal:  Med Oncol       Date:  2014-09-14       Impact factor: 3.064

9.  Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib.

Authors:  Kai Wei; Meng Wang; Wei Zhang; Han Mu; Tian-Qiang Song
Journal:  Med Oncol       Date:  2014-05-04       Impact factor: 3.064

10.  Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients.

Authors:  Vincenzo Formica; Jessica Luccchetti; David Cunningham; Elizabeth C Smyth; Patrizia Ferroni; Antonella Nardecchia; Manfredi Tesauro; Vittore Cereda; Fiorella Guadagni; Mario Roselli
Journal:  Med Oncol       Date:  2014-08-23       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.